Explore alternative funding opportunities and how to enter a fast-growing healthcare market in 2019. We bring 100+ Chinese companies and investors seeking partnerships in biotech and pharma products. Meet more decision makers than you can in any event along the year!

China [email protected] Week
Jan 6th, 2019
JW Marriott San Francisco Union Square,
515 Mason St, San Francisco, CA 94102

We are delighted to announce a new lunch talk added to the program:
Lunch Talk Topic:

Navigating Beyond Borders:
Key Strategic Considerations for China BioPharma in a Global Market

James Lee, PhD
Associate Principal, Oncology Lead
Cello Health BioConsulting,
Previously Defined Health

“China has truly emerged as a major player in the pharmaceutical industry.  Propelled by recent changes to regulatory and funding environments supporting China’s aspirations to be a global leader in innovative therapeutics, China is becoming a destination for licensing and partnering deals.  Buoyed by the recent change in HKEX in allowing pre-revenue listings, there has been a significant increase in listings in HK with the high valuations.  China’s intention to develop innovative therapeutics has led to an explosion of licensing and partnering deals.  The increase in Chinese capital investments and deals will lead to an exciting future, but using the recent downswing of HKEX biotech stocks as one metric, one could well argue that there is a need for more analysis as part of the due diligence around those programs worth moving forward, including deeper assessment of scientific merit, clinical utility, global regulatory, clinical, commercial and payer access considerations.”
Our partnering system is open now.  Accepted meetings will be scheduled instantly.  Early scheduling maximizes your meeting success.

Don’t miss this opportunity to meet with leading industry investors and potential partners from China, US, and other counties.

Register Now


Partial Investors List

Job TitleCompany / Organization
Principal11.2 Capital
partnerAnlong Medical Fund
Chief Strategy OfficerBlue Ocean Capital
Managing PartnerCarlyle Global Advisors
Founding PartnerCEC Capital Group
Managing DirectorCedrus Group
Vice PresidentCITICPE
Investment DirectorCowin Capital
Senior Investment ManagerCOWIN Venture
Chief Investment OfficerCure Kids Ventures
PrincipalDelos Capital
DIRECTORDelos Living
Managing DirectorEfung Capital
managing directorFosun capital
AssociateFrazier Healthcare Partners
CEOGlobalReach BI
PartnerGood Health Capital New York
Venture Capital AssociateGreenSky Capital
PartnerGrey Sky Venture Partners
Managing DirectorH&Q Asia Pacific
PrincipalHemi Ventures
Managing PartnerHemi Ventures
AssociateIllumina Ventures
Managing DirectorJina Ventures Inc.
PartnerJoyance Partners
VPKaitai Capital
Vice PresidentKaitai Capital
Managing PartnerKPCB China
CEOLoncar Investments
InvestorLumira Ventures
Founder and CEOMedTecX
PartnerMomentum Biotech
Managing DirectorMorningside Ventures
Senior AdvisorNorthern Light Venture Capital
Managing PartnerOcean Pine Capital
Founder and CEOOniX Venture
Vice PresidentOrbiMed
Senior Managing DirectorOrbiMed Israel
Investment AdvisorPar Equity HealthTech Fund
VP and Head of International BDSalubris Pharma
VPSequoia Capital
Managing DirectorSequoia Capital China
Co-founder and Chief ScientistShenzhen Lucky Source Investment Management Corporation
Co-founderShiyu Investment Management Co.,Ltd
CSOShiyu Investment Management Co.,Ltd
Investment DirectorShiyu Investment Management Co.,Ltd
Head of Healthcare Corporate FinanceSilicon Valley Bank
CEOSunForest Capital
Managing PartnerSVE Capital
Investment DirectorTaikang Asset Management Co. Ltd.
investment managerTsingyuan Ventures
Managing PartnerTurret Capital Management
Venture PartnerVelocity Partners Fund
Investment AssociateWestlake Ventures
Project ManagerYuhan USA